EP3654971A4 - Compositions contenant des conjugués d'analogues cannabinoïdes et procédés d'utilisation associés - Google Patents

Compositions contenant des conjugués d'analogues cannabinoïdes et procédés d'utilisation associés Download PDF

Info

Publication number
EP3654971A4
EP3654971A4 EP18835211.6A EP18835211A EP3654971A4 EP 3654971 A4 EP3654971 A4 EP 3654971A4 EP 18835211 A EP18835211 A EP 18835211A EP 3654971 A4 EP3654971 A4 EP 3654971A4
Authority
EP
European Patent Office
Prior art keywords
methods
compositions containing
cannabinoid analog
analog conjugates
containing cannabinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18835211.6A
Other languages
German (de)
English (en)
Other versions
EP3654971A1 (fr
Inventor
Jerry L. Bryant, Jr.
David J. Yang
Jana Rauvolfova
Tori STRONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vyripharm Enterprises LLC
Original Assignee
Vyripharm Enterprises LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vyripharm Enterprises LLC filed Critical Vyripharm Enterprises LLC
Publication of EP3654971A1 publication Critical patent/EP3654971A1/fr
Publication of EP3654971A4 publication Critical patent/EP3654971A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0421—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP18835211.6A 2017-07-18 2018-07-18 Compositions contenant des conjugués d'analogues cannabinoïdes et procédés d'utilisation associés Withdrawn EP3654971A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762533894P 2017-07-18 2017-07-18
PCT/US2018/042707 WO2019018536A1 (fr) 2017-07-18 2018-07-18 Compositions contenant des conjugués d'analogues cannabinoïdes et procédés d'utilisation associés

Publications (2)

Publication Number Publication Date
EP3654971A1 EP3654971A1 (fr) 2020-05-27
EP3654971A4 true EP3654971A4 (fr) 2021-04-21

Family

ID=65016693

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18835211.6A Withdrawn EP3654971A4 (fr) 2017-07-18 2018-07-18 Compositions contenant des conjugués d'analogues cannabinoïdes et procédés d'utilisation associés

Country Status (10)

Country Link
EP (1) EP3654971A4 (fr)
JP (1) JP2020527589A (fr)
KR (1) KR20200031663A (fr)
CN (1) CN111065391A (fr)
AU (1) AU2018302155B2 (fr)
CA (1) CA3070538A1 (fr)
EA (1) EA202090116A1 (fr)
IL (1) IL272060A (fr)
MX (1) MX2020000673A (fr)
WO (1) WO2019018536A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022539523A (ja) * 2019-06-24 2022-09-12 ダイヴァース バイオテック， インコーポレイテッド カンナビノイド抱合分子
JP2022552373A (ja) 2019-10-15 2022-12-15 ダイヴァース バイオテック， インコーポレイテッド コンジュゲート分子
CN112807301A (zh) * 2020-12-30 2021-05-18 福建省中科生物股份有限公司 麻类植物提取化合物Cannabiorcol在制备抗肿瘤药物上的用途
US20220305148A1 (en) * 2021-03-26 2022-09-29 Vyripharm Enterprises, Inc. Natural cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases
US20220305145A1 (en) * 2021-03-26 2022-09-29 Vyripharm Enterprises, Inc. Compositions and methods for diagnosing viral infections including covid-19 and for infection severity monitoring as well as targeted detection of cytokine storm
US11554184B2 (en) 2021-03-26 2023-01-17 Vyripharm Enterprises, Inc. Synthetic cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009479A1 (fr) * 2003-06-30 2005-02-03 Merck & Co., Inc. Modulateurs radiomarques du recepteur de cannabinoide-1
JP2009534381A (ja) * 2006-04-19 2009-09-24 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム 細胞画像化および治療のための組成物および方法
US8367714B2 (en) * 2007-08-28 2013-02-05 Vanderbilt University Cannabinoid receptor targeted agent
US20120288442A1 (en) * 2011-05-11 2012-11-15 Atomic Energy Council-Institute Of Nuclear Energy Research Nuclear Imaging Method Using Molecular Target Detection Agent for Liver Fibrosis
EP2992880A1 (fr) * 2014-09-04 2016-03-09 Fundació Institut de Recerca de l'Hospital de la Santa Creu l Sant Pau Utilisation d'inducteurs d'hème oxygénase -1 et du récepteur 2 de cannabinoïdes ou d'agonistes du récepteur opioïde delta dans la douleur inflammatoire
GB201417067D0 (en) * 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRAU SIMONA ET AL: "Pyrazole-type cannabinoid ligands conjugated with fluoro-deoxy-carbohydrates as potential PET-imaging agents: Synthesis and CB1/CB2 receptor affinity evaluation", JOURNAL OF FLUORINE CHEMISTRY, ELSEVIER, NL, vol. 152, 18 March 2013 (2013-03-18), pages 166 - 172, XP028576425, ISSN: 0022-1139, DOI: 10.1016/J.JFLUCHEM.2013.03.006 *

Also Published As

Publication number Publication date
CN111065391A (zh) 2020-04-24
AU2018302155B2 (en) 2022-09-15
EA202090116A1 (ru) 2020-05-14
MX2020000673A (es) 2020-07-29
KR20200031663A (ko) 2020-03-24
WO2019018536A1 (fr) 2019-01-24
JP2020527589A (ja) 2020-09-10
EP3654971A1 (fr) 2020-05-27
AU2018302155A1 (en) 2020-02-06
IL272060A (en) 2020-03-31
CA3070538A1 (fr) 2019-01-24

Similar Documents

Publication Publication Date Title
EP3704239A4 (fr) Compositions de casz et procédés d'utilisation
EP3595653A4 (fr) Compositions de plinabuline et leur utilisation
EP3704254A4 (fr) Compositions de cas12c et procédés d'utilisation
EP3576782A4 (fr) Compositions de produit de recombinaison-peptide et leurs méthodes d'utilisation
EP3630199A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3630788A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3630789A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3436061A4 (fr) Compositions de conjugués saccharide-polypeptide polymérisables et leurs procédés d'utilisation
EP3600325A4 (fr) Nouvelles compositions et méthodes
EP3569671A4 (fr) Dérivé de méthylmenthol et composition conférant une sensation de fraîcheur en contenant
EP3654971A4 (fr) Compositions contenant des conjugués d'analogues cannabinoïdes et procédés d'utilisation associés
EP3691677A4 (fr) Compositions de conjugués saccharide-polypeptide et leurs procédés d'utilisation
EP3600372A4 (fr) Compositions de synthékine et procédés d'utilisation
EP3435956A4 (fr) Compositions photo-stabilisées et leurs procédés d'utilisation
EP3595699A4 (fr) Conjugués peptidiques d'écotropisme du cartilage et leurs méthodes d'utilisation
EP3624773A4 (fr) Compositions ophtalmiques et leurs procédés d'utilisation
EP3634390A4 (fr) Compositions antimicrobiennes comprenant des cannabinoïdes et leurs méthodes d'utilisation
EP3761972A4 (fr) Compositions bioréactives et leurs procédés d'utilisation
EP3688011A4 (fr) Compositions peptidiques et procédés d'utilisation de ces compositions
EP3666729A4 (fr) Composition contenant du nano-soufre et application associée
EP3802553A4 (fr) Compositions contenant du silicium et procédés d'utilisation associés
EP3568469A4 (fr) Compositions de cellules car-t dirigées contre hla-dr et leurs procédés de fabrication et d'utilisation
EP3829307A4 (fr) Compositions de bismuth-thiol et méthodes d'utilisation
EP3496768A4 (fr) Compositions antimicrobiennes et procédés d'utilisation associés.
EP3674375A4 (fr) Composition durcissable et son utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200214

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031415000

Ipc: A61K0051040000

A4 Supplementary search report drawn up and despatched

Effective date: 20210319

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 51/04 20060101AFI20210315BHEP

Ipc: A61K 47/54 20170101ALI20210315BHEP

Ipc: A61P 25/00 20060101ALI20210315BHEP

Ipc: A61P 29/00 20060101ALI20210315BHEP

Ipc: A61P 35/00 20060101ALI20210315BHEP

Ipc: C07D 257/02 20060101ALI20210315BHEP

Ipc: C07D 403/12 20060101ALI20210315BHEP

Ipc: C07D 405/12 20060101ALI20210315BHEP

Ipc: A61K 31/415 20060101ALI20210315BHEP

Ipc: A61K 31/4353 20060101ALI20210315BHEP

Ipc: A61K 31/437 20060101ALI20210315BHEP

Ipc: C07D 231/00 20060101ALI20210315BHEP

Ipc: C07D 231/10 20060101ALI20210315BHEP

Ipc: C07D 231/14 20060101ALI20210315BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230201